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he assertion that the clinical efficacy of antide-
pressants is comparable between—and within—the
classes
1 may be true from a statistical viewpoint,but is of
limited value in practice.Indeed,depression is,clinically
and biologically,a heterogeneous illness and several lines
of evidence suggest that the response to a pharmacolog-
ical treatment depends on the patient’s biological state.
2
Despite advances in psychopharmacology, more than
one-third of patients do not respond to the drug of first
choice.
3 Therefore,a major issue is not only to have effi-
cacious drugs,but also to optimize their use.
T
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Depression is both clinically and biologically a heterogeneous entity. Despite advances in psychopharmacology, a signif-
icant proportion of depressed patients either continue to have residual symptoms or do not respond to antidepressants.
It has therefore become essential to determine parameters (or predictors) that would rationalize the therapeutic choice,
taking into account not only the clinical features, but also the “biological state,” which is a major determinant in the
antidepressant response. Such predictors can derive from bioclinical correlates and, in this context, the neuroendocrine
strategy appears particularly suited. Numerous studies have investigated neuroendocrine parameters—derived mainly
from dynamic challenge tests—in order to (i) determine the predictive profiles of good clinical responders to given anti-
depressants; (ii) monitor the progression of markers in parallel with the clinical outcome; and (iii) evaluate “in vivo” in
humans the mechanisms of action of antidepressant compounds (before, during, and after treatment). This article does
not attempt to be exhaustive, but rather uses selected examples to illustrate the usefulness of the investigation of the
adrenal and thyroid axes and the assessment of central serotonergic, noradrenergic, and dopaminergic systems by means
of neuroendocrine tests. Given methodological constraints, most of these investigations—except for baseline hormone
values and the dexamethasone suppression test—cannot be used routinely in psychiatry. Despite these limitations, the
neuroendocrine strategy still offers new insights in biology and the treatment of depression. Its possible expansion
depends mainly on the development of specific agonists or antagonists for better investigation of the receptors sup-
posedly involved in the pathophysiology of depression. These investigations will help define more homogeneous sub-
groups from a bioclinical and therapeutic viewpoint.  
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During the past years,there has been increasing interest
in the identification of predictors of outcome in depres-
sion.However,there is little consensus regarding which
clinical and biological variables influence the therapeu-
tic response to antidepressants.
4,5 Among the possible
predictors,those derived from neuroendocrine investi-
gations have been extensively studied.These predictors
can be measured at baseline (ie,after a sufficient drug-
withdrawal period) and/or during the course of treat-
ment.It is beyond the scope of this article to detail the
numerous endocrine indicators that can be used as
potential biological predictors of outcome.Rather,this
paper illustrates,through selected examples,the useful-
ness of some pertinent neuroendocrine investigations.
HPA axis
Considerable research findings have accumulated over the
last four decades regarding the role of the hypothalamic-
pituitary-adrenal (HPA) axis in the psychobiology of
depression.
6 Increased cortisol secretion and failure to sup-
press cortisol in response to dexamethasone,a glucocorti-
coid agonist,have been consistently associated with severe,
melancholic, and psychotic depression.
7-9 It has been
hypothesized that this stress axis overdrive is primarily a
reflection of abnormal limbic-hypothalamic activation,with
increased secretion of hypothalamic corticotropin-releas-
ing hormone (CRH) and consequent excessive adrenal
cortisol secretion.However,it remains uncertain whether
the hypercortisolism is an epiphenomenon or directly con-
tributes to depressive symptomatology and to the bio-
chemical alterations seen in major depression (Figure 1).
10
The dexamethasone suppression test
Although the exact pathophysiology underlying dexa-
methasone suppression test (DST) nonsuppression
remains unclear,it has been suggested that abnormal cor-
tisol response reflects impaired negative feedback at the
level of the pituitary corticotroph (ie,decreased type II
glucocorticoid receptor function) on endogenous HPA
axis hyperactivity (ie, increase in hypothalamic CRH
drive that overrides the action of dexamethasone).
11-13
However,(i) cortisol nonsuppression following DST is
not specific for the diagnosis of major depression;and (ii)
the sensitivity of the DST in depression is low.Indeed,
only 15% to 25% of major depressed patients are non-
suppressors,while the rate of positive DST increases in
severe depression (about 40% to 70%).
14 Despite these
limitations,the use of DST in psychiatric research still has
considerable merit.For example,serial DST monitoring
Selected abbreviations and acronyms
ACTH adrenocorticotropic hormone
CRH corticotropin-releasing hormone
DA dopamine
DST dexamethasone suppression test
GH growth hormone
HPA hypothalamic-pituitary-adrenal (axis)
HPT hypothalamic-pituitary-thyroid (axis)
NA noradrenaline
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SSRI selective serotonin reuptake inhibitor
T3 triiodothyronine
T4 thyroxine
TRH thryotropin-releasing hormone (protirelin)
TSH thyroid-stimulating hormone (thyrotropin)
Figure 1. Overview of the relationships between the monoamine systems
and the hypothalamic-pituitary-thyroid (HPT) and hypothalamic-
pituitary-adrenal (HPA) axes. 5-HT, serotonin; NA, noradrenaline;
DA, dopamine; monoamine receptors, 5-HT1A, α2-adrenorecep-
tor, DA-D2; ACTH, adrenocorticotropic hormone; CRH, corti-
cotropin-releasing hormone; TRH, thyrotropin-releasing hormone;
TSH, thyroid-stimulating hormone. + and – arrows indicate stim-
ulation and inhibition, respectively, of the secretion of monoamines
and hormones.
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of depressed patients undergoing drug treatment showed
that DST gradually turned into suppression in treatment
responders.
15,16 Patients whose DST remained abnormal
or who were initially suppressors,but became nonsup-
pressors during an observation period, had a poorer
prognosis.
6,17 In addition,over a long-term follow-up,DST
suppressors at baseline have a better outcome than non-
suppressors.
18Although conflicting results on the predic-
tive value of the DST have been reported,it is generally
accepted that (i) the presence of an abnormal DST indi-
cates the need for a biological treatment,while (ii) the
initial DST status has no predictive value in the choice of
prescription of antidepressants.
19
The combined DEX/CRH test
After CRH became available for clinical studies,a more
sensitive test than the DST was developed: the com-
bined dexamethasone/corticotropin-releasing hormone
test (DEX/CRH test)
20 in which dexamethasone-pre-
treated subjects receive a single dose of CRH during the
afternoon of the next day. In healthy control subjects,
owing to the normal inhibiting activity of the glucocor-
ticoid receptors at the pituitary level, CRH administra-
tion induces only a small amount of corticotropin 
(adenocorticotropic hormone [ACTH]) and cortisol
secretion. In depressed patients, the ACTH/cortisol
response to the combined DEX/CRH test is significantly
increased compared with controls. This phenomenon
suggests an altered glucocorticoid feedback regulation
(ie, decreased glucocorticoid receptor sensitivity), pos-
sibly associated with hypothalamic CRH and vaso-
pressin overdrive.
21
The combined DEX/CRH test identifies HPA axis dys-
function with high sensitivity in severe major depression
(about 80%).
20 Furthermore,DEX/CRH test normaliza-
tion typically precedes or coincides with—rather than fol-
lows—clinical recovery,and failure to normalize portends
poorly for clinical outcome.
22 Patients with persistent
severe HPA dysregulation are more prone to relapse
within 6 months than those with low cortisol response to
the DEX/CRH test at discharge.
23 Moreover, early
improvement (after 1 or 2 weeks of therapy) and bene-
ficial treatment outcome after 6 weeks are associated
with a lower HPA system activity.
21
Taken together,these studies suggest that lowering HPA
activity and clinical response are related.However,in a
recent study,Watson et al
24 have found that the DEX/CRH
remains abnormal in remitted bipolar patients,suggesting
that HPA axis dysfunction is a potential “trait”marker in
bipolar disorder.
Effects of antidepressants on the HPA axis
Recent research suggests that antidepressants could exert
their clinical action in depression via the restoration of
type II glucocorticoid receptor function with a subse-
quent reestablishment of HPA axis negative feedback.
25
Indeed, animal studies
26 have consistently shown that
antidepressants (ie,tricyclics,selective serotonin reuptake
inhibitors [SSRIs], moclobemide, tianeptine) increase
type II and type I (or mineralocorticoid) receptor expres-
sion and function (ie,increased efficiency of signal trans-
duction by increasing mRNA levels and hormone-bind-
ing activities).This,in turn,is associated with enhanced
negative feedback by endogenous glucocorticoids,and
thus with reduced HPA axis activity.Downstream con-
sequences of lowered cortisol secretion is a lessening of
expression of genes that are under corticosteroid regula-
tory control,among them those related to biogenic amine
neurotransmission.
Additional evidence indicates that cortisol-lowering
treatments (ie,“antiglucocorticoids”) may be of clinical
benefit in depressed patients. Indeed, open and con-
trolled trials suggest that blockers of cortisol synthesis
(ie,metyrapone,ketoconazole,aminoglutethimide),or
type II glucocorticoid receptor antagonists, including
mifepristone (RU-486) and ORG 34517,may exert anti-
depressant effects.
27Although clinical usage of the cur-
rently available antiglucocorticoids is limited by signifi-
cant side effects, the development of drugs that
specifically target the glucocorticoid receptor may lead
to innovative strategies in the treatment of depressive
states.In the same way,development of effective CRH
blockers
28 will provide an important tool for further study
of the role of CRH hypersecretion in severe depression
and other stress-related illnesses.
HPT axis
It is well established that major depression may be
accompanied by a dysfunction of the hypothalamic-pitu-
itary-thyroid (HPT) axis,including a slight elevation of
serum thyroxine (T4), subnormal (or “blunted”) thy-
rotropin (thyroid-stimulating hormone [TSH]) response
to morning injection of protirelin (thryotropin-releasingClinical research
276
hormone [TRH]), and a loss of the nocturnal rise in
TSH.
29 Usually, this phenomenon is not secondary to
hypercortisolism.
30,31 Investigation of the HPT axis by
means of the TSH response to morning administration of
TRH (at 8 AM or 9 AM) has limited clinical value because
of modest diagnostic sensitivity (about 25%).
30 Owing to
the circadian activity of the thyrotroph,which is maximal
between 11 PM and 1 AM pituitary TSH secretion is more
sensitive to TRH stimulation in the evening than in the
morning, both in normal controls
31,36 and in depressed
patients.
31,37 In 1990,our group
31 reported that the 11 PM
TRH-TSH test was more sensitive than the 8 AM TRH-
TSH test, and that the difference in TSH response
between 11 PM and 8 AM TRH tests (∆∆TSH) was an
even more sensitive measure.Consistent with our origi-
nal observation,this chronobiological index is reduced in
about 80% of major depressed inpatients.
37-39
It has been suggested
30 that blunted TRH-induced TSH
stimulation might reflect downregulation of the TRH
receptors in the pituitary gland secondary to a prolonged
increase in hypothalamic TRH stimulation.Furthermore,
the shift to higher iodothyronine levels in euthyroid
depressed inpatients, both in the morning
40 and in the
evening,
37 may contribute to the blunting of TSH
response to TRH.
41,42
Predictive value of the TRH test
So far,studies of the therapeutic predictive value of the
TSH response to TRH test have yielded conflicting
results.
30,43 Some studies have found that the normaliza-
tion of the test is associated with remission,in which case
the blunted TSH response—and more obviously the
reduced ∆∆TSH values—may be considered as a “state”
marker of depression.
38 Conversely, persistence of
blunted responses during remission could represent a
“vulnerability”marker to depression.
Some investigators
43 have found no link between the ini-
tial status of the TRH test and the subsequent response
to a particular antidepressant treatment defined accord-
ing to its biochemical mechanism of action. Others
44
have found an association between the blunted TSH
response and the response to desipramine (which shows
a predominant “noradrenergic” action). On the other
hand,it has been observed that patients with the lowest
pretreatment evening TSH secretion (basal and after 
11 PM TRH stimulation) have the lowest rate of antide-
pressant response, and this may contribute to antide-
pressant treatment resistance.
38 In such cases,it has been
speculated that adjunction of thyroid hormones,
45 could
be particularly beneficial to amplify antidepressant
effects,since,by increasing the negative feedback on the
hypothalamus, thyroid hormones may decrease TRH
overproduction at this level.
To date, only one study has examined the relationship
between morning and evening TSH and prolactin (PRL)
response to TRH tests prior to antidepressant treatment
and 12-month outcome.
46 In this study, dissociation
between 11 PMTRH-induced TSH and PRL stimulation
(ie,blunted TSH response associated with normal PRL
response) was indicative of poor clinical outcome.Thus,
normal PRL response to TRH,despite decreased TRH
receptor responsiveness, might reflect a decrease in
dopaminergic tone,since dopamine (DA) inhibits PRL
secretion. In such patients, one may hypothesize that
adjunctive therapy with DA agonists might be useful to
amplify antidepressant effects.
Effects of antidepressants on the HPT axis
A number of reports suggest that treatment with antide-
pressant drugs leads to changes in thyroid function tests:
either decreased peripheral thyroid hormone levels
and/or increased TSH levels (basal or post–TRH stimu-
lation).
47-52 However,these results have not always been
confirmed,
53-58 owing in part to methodological limita-
tions, eg, small sample sizes, variable definitions of
depression,hospitalization status,and technical factors,
such as differences in the sensitivity of the assays used in
the measurement of thyroid hormones and TSH.
Furthermore,it remains unclear whether changes in thy-
roid function are a direct effect of an antidepressant on
the thyroid axis or a correlate of clinical improvement.
Animal studies
58,59 suggest that chronic antidepressant
treatment decreases thyroid function. However, data
from healthy volunteers support the notion that tricyclic
antidepressants have no consistent effect on TSH secre-
tion.
60,61 In depressed patients,most studies have shown
that antidepressant treatment with tricyclics,
49,55,61 SSRIs,
58
or monoamine oxidase inhibitors (MAOIs)
62 does not
induce significant changes in TSH levels.Moreover,it has
been reported,
45,47 but not consistently,
63 that response to
tricyclic antidepressants is associated with (i) higher pre-
treatment T4 levels;and (ii) decreased measures (within
the normal range) of T4 and free thyroxine (FT4) without
changes in triiodothyronine (T3) or TSH levels. Thus,Neuroendocrine predictors of the evolution of depression - Duval et al Dialogues in Clinical Neuroscience - Vol 7 . No.3 . 2005
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although this is not supported by all studies,changes in
thyroid function appear to be related to clinical recovery
rather than to a direct effect of the antidepressant drug.
This is further supported by the fact that normalization
of the ∆∆TSH test is related to clinical recovery,while,
irrespective of outcome,∆∆TSH values are not signifi-
cantly changed by 4 weeks of treatment with amitripty-
line,fluoxetine,toloxatone,venlafaxine,or tianeptine.
38,64
Neuroendocrine investigations of the 
noradrenergic system
The original catecholamine depletion hypothesis of
depression has been reformulated into the “noradrener-
gic dysregulation hypothesis,”
65 which emphasizes a pri-
mary subsensitivity or downregulation in nerve terminal
α2-adrenoreceptors,leading to impaired negative feed-
back on presynaptic neurons,which in turn may induce
a disinhibition of noradrenaline (NA) output and exag-
gerated NA release in response to any activation of the
catecholaminergic system.One of the most consistently
reported abnormal findings in depression is a blunted
growth hormone (GH) response to acute administration
of clonidine, a partial α2-adrenoreceptor agonist.This
suggests subsensitive postsynaptic α2-adrenoreceptors at
the hypothalamic level.A dysregulation of the NA sys-
tem may lead to increased anxiety in depressive
patients.
66,67 More generally, blunted GH response to
clonidine does not appear specific to depression, but
rather to the “anxiety spectrum,”since this blunting has
also been observed in generalized anxiety disorder,
68
panic disorder,
69,70 and social phobia.
71The link between
anxiety and NA dysregulation in depressed patients is
further supported by the negative correlation between
GH response to clonidine and the severity of anxiety as
evaluated by the Hamilton Anxiety Scale scores.
72
Predictive value of the clonidine test
Some studies have shown that remitted depressive
patients show reduced GH responses to clonidine,
73,74 sug-
gesting that decreased sensitivity of α2-adrenergic recep-
tors may represent a vulnerability marker for depression.
This is further supported by the fact that,despite having
differing mechanisms of action,antidepressants such as
desipramine,mianserin,clorgyline,amitriptyline,and flu-
oxetine do not restore clonidine’s effect on GH secretion
in responders or nonresponders to treatment.
75,76
It has also been argued that deficiencies in NA function
could lead to differential response to noradrenaline and
serotonin reuptake inhibitors.
77 In a study by Coote et
al,
78 the decreased GH response before treatment was
correlated with subsequent good clinical response to
desipramine (a “noradrenergic” antidepressant). In a
recent study,Correa et al
79 reported that amitriptyline,
which primarily increases NA function,was more effica-
cious than fluoxetine in depressed patients showing at
baseline blunted GH to clonidine (amitriptyline is at least
100 times more potent than fluoxetine in the inhibition
of the noradrenaline transporter
80).Taken together,these
results suggest that the NA function might influence
response to antidepressant treatment.
Neuroendocrine investigations 
of the DA system
It is known that the mesolimbic DA system plays a key
role in goal-directed and motivational behavior. In
depression,it has been suggested that hypofunction in
mesolimbic DA system may be involved in anhedonia
and amotivational apathy.
81 DA agonists can facilitate the
action of antidepressant drugs in certain animal models
of depression and in some depressed patients.
82
According to the neuroendocrine challenge paradigm,hor-
mone responses to DA agonists may provide an indirect
assessment of central DA neurotransmission at the post-
synaptic receptor level within the limbic-hypothalamic-
pituitary axis in humans.
83,84Apomorphine,a direct-acting
DA agonist with high affinities for D2 and D3 receptors
85
and a partial agonist at the D1 receptor,
86 decreases PRL
and stimulates GH,
84ACTH,and cortisol secretion.
87-89 In
major depression,discrepant findings have been reported:
unaltered responses
76,88-90 or decreased GH response
77,91 to
apomorphine have been found.Some of these divergences
may be explained by the diversity of factors that influence
the hormonal response to apomorphine,and by the het-
erogeneity of the populations studied. Indeed, when
depressed patients are classified according to their clini-
cal features,differences in the apomorphine response are
observed between subtypes. For example, it has been
found,
88,92,93 but not by all,
90 that apomorphine produces a
lesser decrease in serum PRL levels in bipolar patients than
in normals and in unipolar patients. On the other hand,
unipolar patients with melancholic and psychotic features
often show reduced ACTH/cortisol responses especially
when hypercortisolism coexists.
94From a pathophysiological viewpoint (i) blunted PRL
response to apomorphine may reflect decreased D2
receptor function in the pituitary (ie,lactotrophs);and
(ii) blunted ACTH/cortisol response may reflect
decreased DA receptor function (ie,D2 receptor–like or
D1 receptor,or both) connected with the regulation of
the HPA axis at the hypothalamic level.
Predictive value of the apomorphine test
Some preclinical studies suggest that long-term antide-
pressants upregulate and/or hypersensitize postsynaptic
DA receptors (ie,D2 and D3)
95—as reflected by increased
apomorphine responses in animals treated with several
classes of antidepressants.However,in depressed patients,
changes in DA function (ie,increased ACTH/cortisol,but
not GH and PRL,responses to apomorphine) following
antidepressants appear to be transient (ie,after 2 weeks’
treatment,but not after 4 weeks).These changes are not
correlated with clinical efficacy and are independent of the
compound administered (venlafaxine,tianeptine).
64
On the other hand, it has been found that greater DA
postsynaptic sensitivity (assessed by greater GH response
to apomorphine) is associated with greater resistance to
paroxetine treatment. This finding has lead to the
hypothesis that pretreatment low DA receptor respon-
sivity could predict antidepressant response to SSRIs.
96
Endocrine disorders
Endocrine disorders are among the factors that should be
routinely searched for in the management of depressed
individuals. Rare cases of endocrine disorder–related
depression can be identified through the systematic mea-
surement of some parameters,eg,TSH/FT4/FT3,PRL,cor-
tisol/ACTH,parathyroid hormone/calcium,and glucose.
Moreover,it has been well documented that endocrine dis-
orders are factors that may contribute to treatment resis-
tance.
14The dexamethasone test is also used by endocri-
nologists and this test can be used routinely in psychiatry
because it is simple and has decent sensitivity and predic-
tive value in clinical evolution and response to treatment.
Conclusions
The findings reviewed in this article add further to the
body of data pointing to the utility of neuroendocrine
measurement in discriminating among subtypes of
depressive disorders. Depression is characterized by a
complex configuration of disturbances in a number of
neurotransmitter and hormonal systems.Given the mul-
tiple reciprocal relationships between these systems,it is
not appropriate at the present to consider one system as
primary in an etiological sense.
Moreover, the biological changes that can be studied
(“biological states of depression”) not only result from
the pathophysiological process involved in the etiology
of depression, but also from adaptive processes that
maintain the homeostasis of the systems.This is why,in
basal conditions, it is rare to find significant biological
abnormalities in depressive states.In contrast,dynamic
challenges destabilize the homeostatic balance and may
therefore be used to better characterize heterogeneous
biological states. Moreover, this characterization may
lead to different therapeutic strategies.
According to many studies,the presence of positive (or
abnormal) neuroendocrine test suggests a need for anti-
depressant somatic therapy of depression,but the pre-
dictive value of these tests need further clarification.
Unfortunately,for methodological,ethical,and economic
reasons,the neuroendocrine tests are rarely performed
in battery (ie,several tests for each patient) and this lim-
its their application from a pathophysiological and ther-
apeutic viewpoint. For instance, in depression, the
absence of chronobiological dysfunction of the thyroid
axis (ie,normal ∆∆TSH) is significantly associated with
decreased serotonergic function, and vice versa.
39
Therefore,the response to ∆∆TSH test may be of great
value since a normal ∆∆TSH test could orientate the clin-
ician towards antidepressants that increase “serotoner-
gic”transmission;while a blunted ∆∆TSH test,which is
often associated with a blunted clonidine test,
97 could ori-
entate the clinician toward antidepressants that increase
“noradrenergic”transmission.
The relationship between neuroendocrine test results
and clinical outcome has mostly been described in retro-
spective study protocols. On the basis of our observa-
tions,and those of others,one may propose the following
strategies,which could be the theme of prospective clin-
ical trials of antidepressants (strategies marked with an
asterisk have not yet been evaluated in depressed
patients):
• SSRI appear to be perfectly suitable for the first-line
treatment for depression,especially when there is no
evidence for chronobiological dysfunction of the thy-
roid axis (normal ∆∆TSH).
Clinical research
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when the GH response to clonidine is blunted and/or
when there is evidence for chronobiological dysfunc-
tion of the thyroid axis (blunted ∆∆TSH).
•“Dopaminergic”antidepressants appear to be suitable
in case of normal TRH-PRL response associated with
blunted TRH-TSH response (performed at 11 PM)
and/or in case of blunted PRL response to apomor-
phine test (which is often observed in bipolar depres-
sion).*
• In case of a positive DST, frequently associated with
severe depression,antidepressant treatment alone will
probably not suffice and therefore calls for a different
approach (ie, adjunction of “antiglucocorticoids” to
antidepressants,or antipsychotics,since in some melan-
cholic/psychotic depressed patients DST is associated
with blunted ACTH/cortisol response to apomorphine,
reflecting a possible presynaptic DA hypersecretion at
the hypothalamic level).
• In case of nonresponse or partial response in patients
with pretreatment 11 PM blunted TRH-TSH response,
one may propose adjunctive thyroid hormone therapy.*
In this indication,T3 seems to be more efficacious than
T4.
98 Since TSH blunting could be secondary to hyper-
secretion of endogenous TRH,it may be that treatment
with exogenous thyroid hormone increases the nega-
tive feedback and, in this way, tends to correct the
hypersecretion of endogenous TRH.Speculating fur-
ther,the return to normal levels of TRH is perhaps part
of the physiological normalization,which is associated
with resolution of a depressive episode.
Finally, it would also be interesting to study the above
strategies in conjunction with pharmacogenomic
approaches. ❏
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Predictores neuroendocrinos de la evolución de la depresión
La depresión es una entidad heterogénea tanto desde un punto de vista clínico como fisiopatológico. A
pesar de los progresos de la psicofarmacología, una proporción significante de pacientes deprimidos o
continuan con sintomas residuales o no responden a los antidepresivos. El poder determinar predictores
que permitan racionalizar la elección de los fármacos teniendo en cuenta no solamente el estado clínico,
sino también el “estado biológico” –puesto que influye en la respuesta terapéutica– parece constituir una
necesidad. Tales predictores pueden ser el resultado de correlatos biológico-clínicos y es en este contexto
que las estrategias neuroendocrinas se pueden aplicar de manera adecuada. El estudio de parámetros
neuroendocrinos esencialmente resultados de pruebas dinámicas ha permitido (1) establecer perfiles de
predicción de buena respuesta a ciertos tratamientos antidepresivos, (2) seguir la evolución de los mar-
cadores en paralelo con la clínica y (3) estudiar los mecanismos de acción de los antidepresivos “in vivo”
en el hombre (mediante estudios antes, durante y después del tratamiento). Este artículo, que no intenta
ser exhaustivo, considera principalmente el interés en psiquiatría de la exploración de los ejes corticotropo
y tiroídeo y de los sistemas centrales serotoninérgico, noradrenérgico y dopaminérgico mediante prue-
bas neuroendocrinas. Mientras tanto, teniendo en cuenta las restricciones metodológicas de la mayor
parte de estas investigaciones –con excepción de los niveles hormonales basales y la prueba de supresión
con dexametasona– es ilusorio considerar las pruebas neuroendocrinas dentro del conjunto de los exá-
menes de rutina. A pesar de estas limitaciones, la estrategia neuroendocrina ofrece innegablemente nue-
vas posibilidades de modelos biológicos y terapéuticos en la depresión. Su expansión futura depende en
gran medida del desarrollo de agonistas o antagonistas más específicos que permitan explorar de manera
más precisa los diferentes receptores supuestamente implicados en la fisiopatología de la depresión. Es
razonable pensar que a futuro este tipo de investigaciones permitirá delimitar subgrupos más homogé-
neos desde una perspectiva tanto biológico-clínica como terapéutica.  47. Joffe RT, Roy Byrne PP, Udhe TW, Post RM. Thyroid function and affec-
tive illness: a reappraisal. Biol Psychiatry. 1984;19:1685-1691.
48. Baumgartner A, Gräf KJ, Kürten I, Meinhold H. The hypothalamic-pitu-
itary-thyroid axis in psychiatric patients and healthy subjects. Part II.
Repeated measurements of thyroxine, free thyroxine, triiodothyronine, free
triiodothyronine, and reverse triiodothyronine in patients with major
depressive disorders and schizophrenia and healthy subjects. Psychiatry Res.
1988;24:283-305.
49. Winokur A, Amsterdam JD, Berwish N, Phillips JL, Maislin G. The rela-
tionship between the change in thyrotropin response to TRH and thera-
peutic response to desipramine in depressed patients. Biol Psychiatry.
1989;25:207A.
50. Joffe RT, Singer W. Effect of tricyclic antidepressants on thyroid hormone
levels in depressed patients. Pharmacopsychiatry. 1990;23:67-69.
51. Stein MB, Uhde TW. Thyrotropin and prolactin responses to protirelin
(TRH) prior to and during chronic imipramine treatment in patients with
panic disorder. Psychoneuroendocrinology. 1990;15:381-389.
52. Loosen PT. The thyroid state of depressed patients. Clin Neuropharmacol.
1992;15:382A-383A.
53. Leichter SB, Kirstein L, Martin ND. Thyroid function and growth hor-
mone secretion in amitriptyline-treated depression. Am J Psychiatry.
1977;134:1270-1272.
54. Gregoire F, Brauman H, de Bruck R, Corvilain J. Hormone release in
depressed patients before and after recovery. Psychoneuroendocrinology.
1977;2:303-312.
55. Langer G, Schoenbeck G, König G. Evidence for neuroendocrine involve-
ment in the therapeutic effects of antidepressant drugs. In: Brambilla F,
Racagni G, de Wied D, eds. Progress in Psychoneuroendocrinology. New York,
NY: Elsevier North Holland Biochemical Press; 1980:197-208.
56. Linnoila M, Gold P, Potter WZ, Wehr TA. Tricyclic antidepressants do not
alter the thyroid hormone levels in patients suffering from major affective
disorder. Psychiatry Res. 1981;4:357-360.
57. Brambilla F, Scarone S, Massironi R, Nobile P, Pugnetti L. Abnormal ante-
rior pituitary responsiveness to hypothalamic hormones in primary affec-
tive disorder. Neuropsychobiology. 1982;8:269-275.
58. Rosenbaum JF, Fava M, Pava JA, McCarthy MK, Steingard RJ, Bouffides E.
Anger attacks in unipolar depression, Part 2: Neuroendocrine correlates and
changes following fluoxetine treatment. Am J Psychiatry. 1993;150:1164-1168.
59. Atterwill CK, Catto LC, Heal DJ, Holland CW, Dickens TA, Jones CA. The
effects of desipramine (DMI) and electroconvulsive shock (ECS) on the func-
tion of the hypothalamo-pituitary-thyroid axis in the rat. Psychoneuro-
endocrinology. 1989;40:339-346.
60. Laakmann G, Binz A, Voderholzer U, et al. The influence of psychotropic
drugs and releasing hormones on anterior pituitary hormone secretion in
healthy subjects and depressed patients. Pharmacopsychiatry. 1990;23:18-26.
61. Laakman G. Neuroendocrinological findings in affective disorders after admin-
istration of antidepressants. Advances in Biological Psychiatry. Basel, Switzerland:
Karger S; 1980;5:67-84.
62. Joffe RT, Singer W. Effect of phenelzine on thyroid function in depressed
patients. Biol Psychiatry. 1987;22:1033-1034.
63. Linnoila M, Gold P, Potter WZ, Gold PW, Goodwin FK. Tricyclic antide-
pressants do not alter the thyroid hormone levels in patients suffering from
a major affective disorder. Psychiatry Res. 1982;6:271-276.
64. Duval F, Monreal J, Mokrani MC, Crocq MA, Macher JP. Effect of anti-
depressant medication on response to TRH and apomorphine tests in
depression. Biol Psychiatry. 2002;51:123S.
65. Siever LH, Uhde TW. New studies and perspectives on the noradrener-
gic receptor system in depression: effects of the α2-adrenergic agonist cloni-
dine. Biol Psychiatry. 1984;19:131-156.
66. Valdivieso S, Duval F, Mokrani MC, et al. Growth hormone response to
clonidine and the cortisol response to dexamethasone in depressive
patients. Psychiatry Res. 1996;60:23-32.
67. Post RM, Lake CR, Jimmerson DC, et al. Cerebrospinal fluid norepi-
nephrine in affective illness. Am J Psychiatry. 1978;135:907-912.
Neuroendocrine predictors of the evolution of depression - Duval et al Dialogues in Clinical Neuroscience - Vol 7 . No.3 . 2005
281
Paramètres neuroendocriniens prédictifs de l’évolution des états dépressifs
La dépression est une entité hétérogène tant d’un point de vue clinique que physiopathologique. Malgré
les progrès de la psychopharmacologie, environ un tiers des patients ne répondent pas au traitement anti-
dépresseur de première intention. Déterminer des paramètres permettant de rationaliser le choix des chi-
miothérapies en tenant compte non seulement de l’état clinique mais aussi de « l’état biologique » —
puisque celui-ci influe sur la réponse thérapeutique — apparaît par conséquent une nécessité. De tels para-
mètres (ou marqueurs de prédictivité) peuvent être issus de corrélats biologico-cliniques et c’est dans ce
contexte que les stratégies neuroendocriniennes peuvent être appliquées de façon pertinente. De nom-
breuses études ont déjà permis (1) d’établir à partir de paramètres neuroendocriniens —essentiellement
issus de tests dynamiques — des profils prédictifs de bonne réponse à certains traitements antidépresseurs,
(2) de suivre l'évolution des marqueurs parallèlement à la clinique, et (3) d'étudier les mécanismes d'action
« in vivo » chez l'homme d’antidépresseurs (par des études avant, pendant et après traitement). Cet article,
qui ne vise pas à être exhaustif, envisage principalement l’intérêt en psychiatrie de l’exploration des axes
corticotrope et thyroïdien et des systèmes sérotoninergique, noradrénergique et dopaminergique centraux
à l’aide de réponses hormonales à des tests spécifiques. Cependant, compte tenu des contraintes métho-
dologiques de la plupart de ces investigations — hormis les prélèvements basaux et le test à la dexamé-
thasone — il est illusoire d’envisager les tests neuroendocriniens dans le cadre d’examens de routine. En
dépit de ces limitations, la stratégie neuroendocrinienne offre indéniablement de nouvelles possibilités de
modélisation biologique et thérapeutique. Son essor futur dépend pour une grande part du développe-
ment d'agonistes ou d'antagonistes plus spécifiques afin d'explorer de manière plus précise la fonction-
nalité des différents récepteurs supposés impliqués dans la physiopathologie de la dépression. Il est rai-
sonnable de penser qu'à terme ce type d'investigations permettra de délimiter des sous-groupes plus
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